VCs Back ObsEva With $35M For Trials On Pre-term Labor Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
The Swiss start-up will conduct a Phase II study on a compound that may reduce or prevent pre-term labor contractions, licensed from Merck Serono. It hopes to follow in the footsteps of another women's health company, PregLem, which provided exceptional returns with the same CEO and similar investors.